Ascelia Pharma plans to highlight clinical results that demonstrate the efficacy of its Orvigilance oral contrast agent for MRI detection of focal liver lesions at the upcoming RSNA meeting.
Orvigilance is a manganese-based contrast agent designed to enhance MRI scans. Researchers found that it was as effective as a gadolinium-based agent for visualizing and detecting lesions, according to the company.
The U.S. Food and Drug Administration has granted Orvigilance orphan drug designation, and the agent is in a phase III study that consists of 200 patients with severe renal impairment and known or suspected focal liver lesions, according to Ascelia.
